AbbVie and InterMune may have won at least a temporary reprieve in their fight to stop the EMA from releasing trial data on their drugs.
As a pioneer in the fibrosis field, InterMune has often been at the center of considerable buyout buzz. In the spring of 2011, for instance, the company had to pour cold water on fevered speculation that a deal was in the making after its drug Esbriet (pirfenidone) was approved in Europe.
One of the pioneers in the fibrosis drug field is opting to sell off an aging commercial product to help finance its pipeline work and what it hopes will be a final push for its top prospect in the U.S. market.
The roller coaster ride investors have been on for the past two weeks underscores an old bit of market wisdom: when the Dow and other indexes catch a cold, biotech gets pneumonia. By Friday analysts
Shares of Brisbane, CA-based InterMune ( $ITMN ) surged more than five percent yesterday after Bloomberg treated the market to a story that Goldman Sachs had been brought in to scout buyout offers for
Former InterMune CEO Scott Harkonen has been sentenced to six months of home confinement and ordered to pay a $20,000 fine for his part in disseminating a misleading press release in 2002. He also
InterMune ( $ITMN ) took a big step forward today with its announcement that it won European approval for pirfenidone, a new therapy for idiopathic pulmonary fibrosis that is being sold as Esbriet. The
Intermune ( $ITMN ) says it will begin enrollment of another late-stage trial of idiopathic pulmonary fibrosis drug pirfenidone in the first half of 2011. Eight months ago, the FDA rejected the
InterMune ( $ITMN ) has succeeded in Europe where it failed in the U.S. A European panel of experts has backed the company's lung drug Esbriet (pirfenidone) for the treatment of idiopathic pulmonary
Brisbane, CA-based InterMune ( ITMN ) has sold all rights to its promising hepatitis C drug danoprevir to Roche for $175 million in cash and dissolved the collaboration agreement they signed in 2006.